Q2 2019 Earnings Call
<unk> earnings conference call will begin momentarily once again, ladies and gentlemen, thank you for your patience and please standby.
At this time all participants are in a listen only mode. Later, we'll conduct a question and answer session and instructions will follow at that time, if anyone should require operators. That's essentially the conference. Please press Star then tariff on your Touchtone telephone.
I would like to introduce your host for today's conference Mr., John Mills, I see I see our Sir Please go ahead.
Great. Thank you good afternoon, everyone. Thank you for joining us today to discuss the IC you medical financial results for the second quarter of 2019.
On the call today, representing ice you medical isn't that Jane Chief Executive Officer and Chairman.
Scott Lamb, Chief Financial Officer.
And Christian voice lender Chief operating officer.
We wanted to let everyone know that we have a presentation accompanying today's prepared remarks to view. The presentation. Please go to the investor page and click on the events calendar it'll be under the second quarter 2019 events.
Before we started prepared remarks I want to touch upon any forward looking statements made during the call, including beliefs and expectations about the company's future results. Please be aware they are based on the best available information to management and assumptions that are reasonable such statements are not intended to be a representation of future results and are subject to risk and uncertainties future results may differ materially from management's current expectations.
We refer all of you to the company's SEC filings for more detailed information on the risks and uncertainties that have a direct bearing on operating results and financial position.
Please note that during today's call. We will also discuss non-GAAP financial measures, including results on an adjusted basis. We believe we believe these financial measures can facilitate facilitate a more complete analysis and greater transparency and I see you medical's ongoing results of operations, particularly when comparing underlying results from period to period.
We've also included a reconciliation of these non-GAAP measures in today's release and provided as much detail as possible on any attendance that are added back and with that it is my pleasure to turn the call over to go back.
Thanks, John Good afternoon, everybody.
Second quarter fiscal 2019 was a difficult quarter commercially and has caused us to revise our view of profitability for the near and medium term.
Weve largely concluded our integration efforts and delivered our GSK and other cost savings, but this can no longer offset a more competitive commercial environment, primarily in our Ivy solutions segment.
We are executing well towards customers with high service levels and most of our time is spent on external activities, but the reality of the environment forces us to make certain operational changes, which will impact our profitability.
On today's call we wanted to comment on the Q2 results and discuss our current view of the business and recent performance trends explain some of the actions were taken given the market volatility and their financial and operational impact in the back half of the year.
Provide the usual updates on key activities quality and housekeeping items and lastly in briefly reiterate some of our thoughts on the longer term positioning of the company and the opportunity for value creation.
They are unfortunately, not a lot of short stories on Q2.
The company is running well from a systems perspective post cut over but the competitive environment and Ivy solutions and a few lingering production issues caused a decrease in revenues and profitability.
The income statement was straightforward with the sequential decrease in revenues led to a sequential decrease in earnings as most of the TSA cost savings have been in the PML since the beginning of the year.
We finished the quarter with approximately 290 million and adjusted revenue adjusted EBITDA came in at $67 million and adjusted EPS came in at $1.99 with cash of $316 million.
Adjusted revenue was down 13% quarter over quarter on a constant currency basis due largely to the comparison of the IB solution shortage in Q2 2018.
And during the quarter, we recorded two charges related to actions, we're taking in our Ivy solutions segment.
Let's start with IB solutions for this call is by as it is by far and away. The main driver of variance for the year.
The segment reported approximately 80 million in revenues and like the last two quarters had substantial declines on a year over year basis at 31% as the 2018 Ivy solution shortage carried to the first half of 2018.
As we've said on previous calls do unique temporary industry issues have largely been resolved, but the changing competitive environment has led to this level of revenues. There has been a lot of volatility in I'd solutions with a huge swing in 2018 between the first half of the year, where our business benefited from the industry shortage to the second half where the industry had substantial destocking weaker underlying demand.
On a year over year basis, clearly the largest driver of variance for US has been volume as our non committed or trade business has substantially eroded and we've had to step in and defend our market share here.
Sequentially without being ultra precise the decline in I'd solutions was two thirds to volume and one third to mix driven primarily in our non committed business.
To put it in more distinct terms as we commented on the last call. We feel that there is real excess capacity in the marketplace. We have built significant safety stock to offer customers supply protection that is now in our permanent supply chain across the two us operated manufacturing sites.
But in categories with this dynamic we feel the logical move is to reduce output to get production more in line with market demand as we know we have to safety inventory buffer that the industry requires plus holding some excess capacity.
When we built our 2019 plans, we assumed we would run somewhere around 100 million a quarter in this business, which was the Annualization of Q4, 2018, plus a little bit.
Given the Q2 results in market behavior, we do not see a reason to produce at this level for the back half of the year as the excess production to date has burdened us with extra supply chain costs, we've produced more inventory than we need right now and the cost to move around in store that inventory can begin to offset the marginal profit of the product pretty quickly.
As a result, we need to take three decisions that impact our PML in Q2, and the back half of the year.
First we've already started to slow down production towards the end of Q2 and kept the Austin plant down for a few extra days post our normal Q3 maintenance shutdown and we'll have some sporadic slowdowns as appropriate over the balance of the year.
As we've said before these are typical manufacturing products that have a high fixed cost component.
And the deceleration of production causes negative variance as we produce at a slower rate.
Second we're going to revise our relationship with Pfizer to also proportionately take less product from Rocky Mount.
We will maintain our manufacturing redundancy as we've always talked about but it makes sense to buy down our contract with Pfizer to take less output.
While the cash payments for this will likely be later, we have decided to take this decision now.
Third we're going to take some action to optimize our current inventory and logistics network immediately to speed up the movement of product through the network basically if you have lower margin products, taking up more space and moving slower through a fixed pipe you find yourself getting backups in the whole system.
Those backups have led to excess supply chain costs, which will take some time to get out of the network.
I'll come back to summarize what this means financially towards the end of my comments, but each of these buckets less revenues, leading to less margin manufacturing variances and excess supply chain cost each impact the balance of 2019 and to some extent beyond.
We have described the volatility in I'd solutions on previous calls, but that doesn't make it much better right now.
We have been very focused on the longer term and we have to make economically rational decisions. Even if they are negative to expectations. It does not make sense to waste capital building inventory that isn't needed for to put good money after bad to keep all the various plates spinning and the hope that we'll sell our way out of this environment.
What we feel reasonable about today in I'd solutions for the longer term is two primary items.
First we feel the quality of our customer book has improved with US holding the best list of sustainable relationships versus the day, when we bought the business.
Second we've survived a bleed out of the vast majority of the non committed trade oriented business, that's still lets us run healthy production environment. After we absorb the necessary slowdowns and shift some production from rocky Mount into our more cost competitive Austin location.
We have been trying to operate with transparency to customers by illustrating the generic drug like regulatory framework high capital expenditures and value and a healthy supply side situation to a business that was historical pricing anomaly.
We have the inventory on hand, continuing excess production capacity to make us a competitive supplier and even with all this commentary we continue to follow our repetitive comments on NPV base behavior, albeit that value has tightened.
Lastly, we continue to be vigilant here on quality with no new commentary.
Again more on tying this back financially in a bit.
Turning to infusion consumables, which is our largest business confusion consumables had revenues of $118 million in Q2, which implied a 3% decline year over year adjusted for currency.
The sequential decline was caused primarily by the timing of some OEM orders on our Swabcap line.
And temporary delays in oncology, which were finally out of today.
US volumes were a little bit lighter than expected, but there was no customer churn anywhere really in the U.S market.
The rest of the market was pretty much as we expected.
This is the segment, where the most advantage now is a joint entity and we have largely rationalize the product portfolio and brought together the operational efficiencies of the combination.
Commercially we have all the pieces all the technology and all the scale to compete globally and should be able to offer more value to the customer.
We have won important new customers and have oncology demand that we can finally now satisfies production has improved we continue to feel positive about this segment into the back half of 2019.
On infusion systems, which is the business of selling pumps dedicated sets and software which is important because it's a business that brings a lot of recurring revenues. This segment at 82 million in revenue, which implies a 4% decline adjusted for currency and it was at the levels we expected.
To give a bit of a longer story on pumps, we have a few different product category areas in which we operate.
The vast majority of our product line is our core plum LDP infusion pumps. This was the product line that the old I assume medical pre deal was deeply dependent on and then had lost significant ground in the us market.
We feel that this line has stabilized for us and we've gotten back to the core marketing message. There has been a number of independent and clinical reviews that have validated our approach to plumbline drives the majority of value and we feel the best we have since we bought the business.
We believe we have stabilized the plum for the first time in years the value creation aspects of real incremental cash flow takes time as it only happens when we improve our install base, but we feel like we're in a good dialogue in a number of geographies.
We have two other much smaller categories, we do participate in the pump line.
One of the two is our specialty pain pumps, which use a proprietary disposable syringe.
This disposables manufactured for us by Pfizer in the Rocky Mount facility.
As most customers already know this line has been on and off again in Rocky Mount.
We've been able to manage it with deep inventory allocations, but it did impact us negatively in Q2 and likely will continue to impact us a bit.
Pfizer is already rebuilt the line months ago, and we expect them to be up and running consistently at some point. This year. We just don't have a specific date and I've been juggling this issue for a while.
We spend a lot of time airtime on integration on the previous calls about how much work, it's been and we don't need to do that anymore.
Q2 service levels to the customer globally, and global fulfillment rates have been very strong and it should be noted we did put a little money and resources here to stabilize in Q1 post cut over.
The only key activity left is the manufacturing sites systems conversion in Austin, which is now scheduled for early next year.
From a quality perspective, there is not really much to report.
Since the last call. We did finish all of our MD SAP inspections at all of our device sites and all concluded positively as we said on the previous call. We did have a full FDA inspection in Salt Lake City Oreos earlier this year with no major findings and we're on the clock for an Austin inspection in our prepared.
We continue to be vigilant and Ics and expect inspection of our other facilities. During this calendar year and we'll update on each call.
Okay to come back to the topic of earnings results, how we think about the near term of 2019 and the future.
The attached slide number five basically shows the call down to our 2019 EBITDA guidance from approximately 325 at the midpoint to a range of $260 million to $275 million.
Ivy solutions revenues are 50% to $60 million less than we annualized coming out of Q4 and the effect of volume reduction in our non committed business and the resulting mix impact leads to 50% of the adjustment are approximately $30 million.
We're done chasing this we are assuming it's at this level from here on out.
Then the absorption adjustment is another 25% and the excess supply chain costs are the remaining 25% at about $15 million each.
This would put the back half quarters at approximately $60 million to $65 million.
The core question is of course, well how much of this is permanent versus temporary.
The margin from less revenues could likely be permanent.
We have always had contingency plans if volumes deteriorated and part of this extra slowdown and move into Austin is to get production to meet demand.
The supply chain costs are extra until the pipe gets flowing at a normal pace.
It will take a minimum of six months from today to get all these activities done. So we would assume it continues into Q1 2020.
As we think about this question right now we're extremely cautious given the competitive environment and volatility in IB solutions. It is safest to assume that we will be $60 million to $65 million EBITDA.
Per quarter for the next few quarters as we work through the issues.
This is the right level of profitability, allowing us to compete in this environment.
Even if Q3 or Q4 revenues comes in higher for Ivy solutions, we still will not change this view.
We have delivered our earnings expectations for 21 quarters in a row, which is extremely hard as a small company and we understand and accept that thats all out the window now, but we have seen the competitive environment change and we need to make sure. We can compete through whatever this cycle is.
We have consistently said that we've been actively calling on customers and trying to illustrate the value we can add to the system and the value to the system and having us as a healthy participant.
While its a long journey, we do believe that this message is resonating.
Feedback on the products continues to be solid the products are necessary for the system had been reliable for many years.
We never assumed it was always the straight line up and we cannot flip our behavior into short term focus even with these changes we will continue investing in R&D appropriate capacity expansion in our production network and into commercial resources to serve our customers.
Our belief in our most differentiated business of IB consumables, and IP systems, and the attractiveness of the industry structure merits. This point of view.
We ultimately will get judged on whether those businesses can expand and create value with the stable Ivy solutions segment. So we have to keep our focus and investment on that.
From a value creation perspective.
We understand and accept that these changes will rebase a view of our potential.
We still have a belief that we will absolutely maximize profitability to the most sensible level in our business like we always have.
We still have a belief that even with a little less cash of these adjustments impact cash.
We have a safe and strong balance sheet that can protect shareholders and be deployed for value creation as opportunities emerge.
We have made significant capital investment into our factories and systems over the last two years and are in the final stages of some major production upgrades.
We still believe the categories are deeply valuable with a number of intrinsic value drivers, including high quality are hard to reproduce production assets sticky product categories, where there is differentiation and we have a set of strong experienced people to do the work.
And we have a culture of not wasting shareholder resources and respect for our capital hence the decisions we want to make as the environment has changed.
As always I'd like to close with things are moving fast we have improved our most differentiated businesses with urgency and we are taking realistic and responsible actions to compete in the realities of the market today and believe we have the tools to do so effectively.
We have hit a big bump, but we will overcome it and emerge stronger.
I really appreciate the effort of all employees to adapt move forward and focus on improving results and our company appreciates. The support we received both from our customers and our shareholders.
With that I will turn it over to Scott.
Thanks, Jack and good afternoon, everyone.
To begin I'll first walk down the PML and then talk a little about cash the balance sheet and the balance of the year.
So we began our second quarter 2019, GAAP revenue was $312 million compared to $360 million.
Down 13% from last year or 12% on a constant currency basis.
For your reference the 2018 and 2019 adjusted revenue numbers, which exclude contract manufacturing sales to Pfizer a cost can be seen on slide number three of the presentation.
Our adjusted revenue for the quarter was $290 million compared to $341 million last year down, 15% or 13% on a constant currency basis.
Infusion consumables were $118 million down, 5% or 3% on a constant currency basis.
Ivy solutions, which we primarily sell in the us were $80 million down 31%.
Infusion systems were $82 million down, 7% or 4% on a constant currency basis.
And critical care was down $2 million.
18% or 17% on a constant currency basis.
Adjusted diluted earnings per share for the second quarter of 2019, or a $1.99 compared to $2.69 for the second quarter last year.
Our tax rate this quarter was favorably impacted by some discrete benefits related to equity compensation.
Now we estimate our tax rate for the full year to be in the range of 17% to 19%.
And finally, adjusted EBITDA decreased 14% to $67 million for the second quarter of this year compared to $77 million last year.
Now as you can see from slide number four of the presentation for the second quarter, our adjusted gross margin was 42%.
Compared to 45% for the second quarter last year.
The three largest drivers for the year over year decrease were one the ramp down of IB solution production and the associated lost overhead absorption.
Two.
Additional supply chain costs related to higher than optimal inventory levels and three.
Cost related to improving customer service levels.
Just as it took us months to ramp up to increase production rates and an expanded distribution network to support the Ivy solutions supply shortages in the market.
It will take us the rest of this year to ramp back down.
And while the majority of these costs are temporary it will take at least six months from today before we see a significant reduction.
For the year, we expect to see gross margins in the 40% to 42% range was clearly implies that the second half will not be similar to the first half due to the operational changes we are making.
As expected year over year STN, a decrease approximately $14 million and the decrease came primarily from CFA savings as a result of separating from Pfizer and standing up the business on our own.
As a percent of revenue R&D expenses were relatively flat year over year.
Restructuring and strategic transaction and integration expenses were $37 million in the second quarter versus $19 million last year.
This includes system integration costs for our Austin manufacturing facility.
And a onetime charge to move our us pump service depot to our existing Salt Lake City facility.
In addition, this includes a onetime cash payment of approximately $22 million to reduce our contracted commitments to Pfizer.
In addition to the $22 million a onetime charge as you can see from slide number four of the presentation.
There was an additional one time charge of $16 million as we restructure our inventory and supply chain around the IB solutions business to match supply with market demand.
Also there was a $40 million noncash adjustment this quarter to the carrying value of our contingent consideration.
Payable to Pfizer, reducing the value of the earn out liability essentially to zero.
Just as a reminder, this is based on reaching a certain three year cumulative earnings target by the end of 2019.
Now moving onto cash in our balance sheet.
For the quarter free cash flow was $3 million and cash remained approximately the same as marches $315 million.
Net working capital decreased slightly in the quarter and due to the changes in our IB solutions business, both internally and in the market.
We expect cash at the year.
To be between 350 and $375 million.
Obviously below our original guidance.
The EBITDA reduction is the largest driver of this and we still have a bit more cash tied up in inventory.
In the second quarter, we spent $20 million on Capex, primarily related to general maintenance system integration capacity expansion for our consumables business and transferring a portion of contracted solutions products from Pfizer to our Austin manufacturing facility.
And as we said on our last call, we still expect to invest in the business this year.
Similar to what we spent last year or approximately $100 million.
Due to the changes in our IP solutions business that we've talked about we are updating our guidance for this year.
And we now expect adjusted EBITDA to be in the range of $260 million to $275 million.
On an adjusted EPS to be in the range of $7 55 to $8.15.
Lastly, I would like to say.
We have finished most of the integration and delivered on our T.F. TSH savings, but due to the more competitive Ivy solutions environment, we have had to make some difficult operational decisions that will impact our profitability.
However, these decisions are necessary for the long term strength of our company.
And with that I'd like to turn the call over for any questions.
Thank you.
Ladies and gentlemen, if you have a question at this time. Please press Star then the number one on your Touchtone telephone. If your question has been answered or you wish to remove yourself from the queue. Please press the pound key.
Prevent any background noise, we ask that you. Please please your line on mute. Once this question has been stated.
Our first question comes from the line of Larry Solow CJS Securities. Your line is open. Please go ahead.
Great. Thank you and good afternoon.
Does that perhaps.
Question on the solution and then one just general question on the on the.
Sort of itemized deductions.
Starting from the bottom on the supply chain cost and you spoke with sort of optimizing their logistics behind that.
I guess two questions that could give us a little more color on what exactly you have to do there and I assume over time that most of this.
Impacts from expenses should wane, maybe within the next whatever that maybe two to three quarters is that fair to say.
Certainly the bottom two on no walk down there are more temporary in nature. We've had on the on the middle bucket. We've had contingency plans on the bottom it's totally a function of inventory coming out of the system and warehouse and shelf space coming out of the system.
It's really hard to take some of the old dated product and other inventory out of the market and its about squeezing down the number of pallet spaces and other things. It's just a high cost to hold this stuff.
Right and the the absorption.
Obviously, you are planning to move more into Austin overtime, which weve you've outlined.
I assume that sort of the remedy in.
Does that plan.
Does it or is there a paying on the overall improvement expectation on that or is that just a little slightly lower level.
Yes at the end of the day for making less pieces you added you have negative absorption right.
For us it's the final equation of how many pieces that we make this year, how many pieces that we make next year, which site do we make them.
Over time, we think we get it back but it requires you get fully up and running into Austin, and we don't want to short of that happens in a quarter right. It took us it took us in earnest nine months to ramp up when we were hustling. We've been added a little bit of time here a couple of weeks, it's going to take a full six months to to to get healthy get this extra capacity.
And it doesn't sound like for better or worse.
You expect another like to drop maybe mostly your.
Most of the current revenue is sort of committed business.
And thats at least a positive.
Correct I would say the.
The.
Non committed or trade whenever you want to call it normal normal business is.
A fraction fraction of what it was when we.
Started.
This business.
But it has been incredibly competitive out there.
And this is as much about the environment changing around us.
And we've tried to incorporate that in what we're saying.
On the earnings perspective to give us the flexibility to handle.
Situations.
Just lastly, I'll just clear the story of the quarter is in the outlook is on the solutions piece, but.
Consumables and fusion system, certainly don't seem to be hitting the cover off the ball your competitors from what I read sounded like.
No no true competitors in different segments of the market, but sounded fairly positive is there any have you seen any.
Decline in the overall market environment, whether it be hostile utilization or anything that would.
Impact you.
No I mean I feel like.
It's a little hard to be totally transparent into what everybody's business as the products are slightly different and people have different levels of installed base that they're renewing and refreshing right, which counted the numbers from quarter to quarter. So I don't know that its always apples to apples I don't think we see any big major structural stuck there. We we did this incredibly complicated cutover and we fell down in a couple of production spots along the way in consumables and we made our comments there on what we believe on the LLP pumps.
Okay.
Thanks I appreciate it.
Thank you and our next question comes from the line of Matthew Mission with Keybanc. Your line is open. Please go ahead.
Great. Thank you very much for taking the questions Novak.
Hey in the face of this.
I mean.
In the same quarter, you had a competitor announce you know about a $1 billion of.
Capacity expansion.
In in Ivy solutions, and you kind of look at any cities of the competitive situation doesn't look like it's going to get any better over the next couple of years is how comfortable are you that this 80 million run rate of contracted volume can can stay at $80 million run rate of contracted volume.
I think Thats a question that we are again trying to incorporate in what our.
Comments are here.
And be cautious for the exact reason, you're saying are again I think some of the capital. That's been publicly disclosed is it nationally for new capacity expansion might differ catch up on things that have happened in the past weakness positioned slightly differently.
But I hope our comments also illustrate kind of what's happening in the industry and.
Also give us the ability to compete in the event the environment changes and we've been chasing this and we're all tired and kind of disappointed around it and so we hope we priced the competitive market into what we are saying right thats by the way we've changed our view of the world.
Right Im not sure I feel comfortable answering that question what is the world three years from now but the idea is obviously to make a smaller portion of our overall portfolio overtime.
Okay.
And then making it like a small portion of the portfolio.
So we want to grow the rest if you want to grow the rest of the business.
Why do you think that that Plum is now is now stable and could start to.
Increased its installed base of over time like what what would what is kind of driven the stability here.
And your ability to maybe come back in certain winning and taking some share.
Yes, I mean, let's let's stick more in the first part of that right because thats been the objective through now which is.
We bought a business where that business line was literally 100% neglected and.
I see you was.
Downstream of that.
We've had it for two years and four months or something now and we've had people out there actively calling on.
Customer it started with that it started with the redefining our value prop to the customer and there has been.
Papers and studies and the like.
And I feel like just the hustle of trying to.
Understand where our installed base was.
And really developing a deeper relationship there as what we've been focused on.
Thats been the primary effort today to it it.
Bled out a lot over a 10 year period, right, but I feel like just calling on the customers and understanding where the businesses and the reason the product was very high market share product at some point in time, we've gotten back to that.
I mean, I don't think we're at the point, yet, where we're saying Hey, we think we're going to.
Grow X y or Z, but we're certainly in the conversations right and that's why the markets competitive.
It's a great time to be a customer out there across the board and I think all the players know that it is it is a healthy vibrant market right now right in our product needs to hang on its own merits and people can do the work to see whether that's the case or not but we've certainly put a lot of time and energy into that.
Okay, and then just last question.
I just want to make sure I understand the commentary around around the safety stock that you built.
Is that.
I mean is that.
Inventory that you're holding in some like warehouses and distribution or is that or is that already in the channel through the distributors.
That you have to work that your customers have to work through.
No that's inventory were holding so one of the reasons you see cash not growing even though we're still decent EBITDA number this year.
His because inventory will be up year over year right the idea that.
On a low priced item everybody sitting around with lots of idled global capacity and move it around really couldn't serve in a catastrophic event anyway right. What really does is products sitting in a warehouse here that is months of coverage and that's the value prop we can offer customer.
Okay, all right. Thank you very much.
Thank you and our next question comes from the line of James Jason Bedford with Raymond James Your line is open. Please go ahead.
Hi.
Good afternoon, and I apologize for the background noise just recap the.
Got to be solution dynamic here, there's a lot of detail but.
Just kind of.
Let me note. This thought process is correct. So you came into the year thinking you were going to do about $400 million in I'd solutions revenue you now seem like you're on track to do about 325 million.
I guess one is that are those numbers.
Jive with your commentary.
Yes.
Okay. So the EBITDA impact from this seems like it's about $60 million, what you're saying is that how.
This is permanent the other half is arguably trends and as you realign inventory and production is that a fair recap of what's going on here.
Yes.
Thanks.
I'd be solution that seems like the implied guide going forward here, it's about 70 576 million a quarter.
Is that primarily in that it was kind of ads.
A little more specific here is that just largely you're committed business, meaning the trading business is pretty much gone.
Yes.
Okay, and that's how we should think about 2020.
As well from a quarterly run rate perspective.
Plus a little bit of wins minus a little bit of losses something around those lines.
Okay.
You mentioned supply constraints impacting both consumable in the pump business.
Is there any way to quantify the impact and I realize it's pretty small in the Grand scheme of the prior discussion, but is there any way to quantify the impact in the quarter and then are these issues behind you.
I prefer not to categorize a quarter I really want the results to speak for them selves, Jason when we put it put it out there.
I think today, we finally have had new production come online in oncology.
That.
Help we got kind of a double whammy with the with the recall we had earlier in the year, we had to take some new parts that have come online to replace things are already in the channel. That's all finally cleaned up.
And so we feel much better about it.
Okay, and just trying to.
I understand the commentary you feel positive on the consumable segment in the second half of the 19 to reinterpret positive as we expect the business to grow that segment to grow year over year.
I, certainly think thats, what what we.
Intent right we were positive on this segment.
All year, and we and our comments at the end of last year getting right. We've just we've had some challenges.
Okay, nothing structurally different years or Havent been big turns one way or the other right Theres theres been more wins that we havent implemented to the time being than losses, we've had out but it just hasn't.
Come into the income statement, yet so ultimately it needs to do that.
Okay.
In terms of the.
Balance sheet, you're sitting on 300, some odd million in cash.
What's the plan with that with that cash that.
Just in there.
I mean, the plan is the same as it was for three years when it's out there before we bump hospira writer to ultimately news it to.
And drive value and capital deployment, we did to authorize a bigger buyback and stuff because we don't know exactly what's going to happen in the marketplace, but fundamentally we believe.
We believe that capital and.
The Unlevered EBITDA, we have is better used to bring other things into the portfolio than anything else than to leverage ourselves more to a concentrated.
Set of product lines right now right.
Okay I apologize.
I Miss it.
Jason the macros are a little bit worse, if you could get some required the grade.
What's the size of the buyback.
You will see in the queue, we opted to 100.
Okay. Thank you.
Thank you and I'm showing no further questions at this time and I would like to turn the conference back over to the CEO of King for any further remarks.
Okay. Thanks, Thanks folks look this is a harder.
Message for us and it is not one that we are frankly have been very familiar with and so we hold ourselves accountable.
All employees are rallying around making this the best company, we can make it and it is never a straight line up and.
We respect People's opinions, and we respect our own capital.
And make sure we do the right thing so.
We are open for any questions comments people know how to find us and.
We'll make ourselves available immediately okay.
Thanks, very much I will talk to everyone soon.
Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect everyone have a great day.